![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Shionogi Begins Human Trials of First Once-A-Day Pill for COVID-19 Patients
Shionogi Begins Human Trials of First Once-A-Day Pill for COVID-19 Patients
![Shionogi logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Shionogi-logo.gif?t=1588107044&width=430)
Japanese drugmaker Shionogi has launched a clinical trial evaluating the first once-daily pill for treatment of COVID-19 patients.
The investigational drug, S-217622, works by inhibiting an enzyme that the SARS-CoV-2 virus needs to make copies of itself inside human cells.
The phase 1 trial will evaluate the small molecule drug’s pharmacokinetic profile, safety and tolerability. No adverse events were observed after the initial dose administered last week, the company said.
Upcoming Events
-
18Jul
-
21Oct